Golden State Wealth Management LLC Acquires 109 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Golden State Wealth Management LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.5% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 863 shares of the biopharmaceutical company’s stock after purchasing an additional 109 shares during the quarter. Golden State Wealth Management LLC’s holdings in Gilead Sciences were worth $97,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of GILD. Redwood Financial Network Corp boosted its stake in shares of Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 98 shares during the last quarter. Nicolet Advisory Services LLC boosted its stake in shares of Gilead Sciences by 2.9% in the 4th quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 100 shares during the last quarter. Peak Financial Advisors LLC boosted its stake in shares of Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $677,000 after purchasing an additional 100 shares during the last quarter. Perkins Coie Trust Co boosted its stake in shares of Gilead Sciences by 2.6% in the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company’s stock valued at $435,000 after purchasing an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. boosted its stake in shares of Gilead Sciences by 33.3% in the 1st quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 100 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the transaction, the chief executive officer directly owned 620,268 shares of the company’s stock, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the sale, the chief financial officer owned 165,110 shares in the company, valued at $18,190,168.70. This represents a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 58,500 shares of company stock valued at $6,340,745. 0.27% of the stock is owned by insiders.

Analyst Ratings Changes

GILD has been the topic of a number of analyst reports. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price objective on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, April 25th. Finally, Oppenheimer lowered their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, April 25th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

Gilead Sciences Price Performance

GILD opened at $111.28 on Monday. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23. The company has a market capitalization of $138.42 billion, a price-to-earnings ratio of 23.43, a P/E/G ratio of 0.72 and a beta of 0.29. The firm’s fifty day moving average price is $107.02 and its two-hundred day moving average price is $104.11. Gilead Sciences, Inc. has a 1 year low of $66.34 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm’s quarterly revenue was down .3% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.32) EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.